101 related articles for article (PubMed ID: 30224273)
1. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
[TBL] [Abstract][Full Text] [Related]
2. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
3. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
[TBL] [Abstract][Full Text] [Related]
4. European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
Opitz I; Bille A; Dafni U; Nackaerts K; Ampollini L; de Perrot M; Brcic L; Nadal E; Syrigos K; Gray SG; Aerts J; Curioni-Fontecedro A; Rüschoff JH; Monkhorst K; Weynand B; Silini EM; Bavaghar-Zaeimi F; Jakopovic M; Llatjos R; Tsimpoukis S; Finn SP; von der Thüsen J; Marti N; Dimopoulou G; Kammler R; Peters S; Stahel RA; Falcoz PE; Brunelli A; Baas P;
J Thorac Oncol; 2023 Sep; 18(9):1233-1247. PubMed ID: 37356802
[TBL] [Abstract][Full Text] [Related]
5. Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
Collins DC; Sundar R; Constantinidou A; Dolling D; Yap TA; Popat S; O'Brien ME; Banerji U; de Bono JS; Lopez JS; Tunariu N; Minchom A
BMC Cancer; 2020 Dec; 20(1):1210. PubMed ID: 33298007
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
Kim RY; Li Y; Marmarelis ME; Vachani A
Lung Cancer; 2021 Sep; 159():107-110. PubMed ID: 34320420
[TBL] [Abstract][Full Text] [Related]
7. Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients.
Lamberti M; Capasso R; Lombardi A; Di Domenico M; Fiorelli A; Feola A; Perna AF; Santini M; Caraglia M; Ingrosso D
PLoS One; 2015; 10(8):e0135331. PubMed ID: 26262875
[TBL] [Abstract][Full Text] [Related]
8. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.
Blum Y; Meiller C; Quetel L; Elarouci N; Ayadi M; Tashtanbaeva D; Armenoult L; Montagne F; Tranchant R; Renier A; de Koning L; Copin MC; Hofman P; Hofman V; Porte H; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; de Reyniès A; Jean D
Nat Commun; 2019 Mar; 10(1):1333. PubMed ID: 30902996
[TBL] [Abstract][Full Text] [Related]
9. Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma.
Dozin B; Carbotti G; Roncella S; Ferro P; Dessanti P; Canessa PA; Ferrini S; Fabbi M
Cancer Immunol Immunother; 2021 Nov; 70(11):3349-3355. PubMed ID: 34003301
[TBL] [Abstract][Full Text] [Related]
10. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
Gordon GJ; Dong L; Yeap BY; Richards WG; Glickman JN; Edenfield H; Mani M; Colquitt R; Maulik G; Van Oss B; Sugarbaker DJ; Bueno R
J Natl Cancer Inst; 2009 May; 101(9):678-86. PubMed ID: 19401544
[TBL] [Abstract][Full Text] [Related]
11. Multimodality Therapy in Patients With Primary Pericardial Mesothelioma.
Offin M; De Silva DL; Sauter JL; Egger JV; Yorke E; Adusumilli PS; Rimner A; Rusch VW; Zauderer MG
J Thorac Oncol; 2022 Dec; 17(12):1428-1432. PubMed ID: 36075530
[TBL] [Abstract][Full Text] [Related]
12. Pleural mesothelioma metastasis of the scalp.
Bicak T; Ozekinci S; İbiloğlu İ
Pol J Pathol; 2023; 74(4):297-301. PubMed ID: 38477094
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma.
Bilecz A; Stockhammer P; Theegarten D; Kern I; Jakopovic M; Samarzija M; Klikovits T; Hoda MA; Döme B; Oberndorfer F; Muellauer L; Fillinger J; Kovács I; Pirker C; Schuler M; Plönes T; Aigner C; Klepetko W; Berger W; Brcic L; Laszlo V; Hegedus B
Histopathology; 2020 Jul; 77(1):55-66. PubMed ID: 32170970
[TBL] [Abstract][Full Text] [Related]
14. Importance of Histopathological Grading for Treatment Selection in Malignant Mesothelioma.
Türk İ; Findik G; Çetin M; Bicakcioglu P; Gülhan SŞE; Aydoğdu K; Yılmaz Ü; Demirağ F
Thorac Cardiovasc Surg; 2023 Sep; 71(6):497-503. PubMed ID: 36736368
[TBL] [Abstract][Full Text] [Related]
15. CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor.
Roncella S; Laurent S; Fontana V; Ferro P; Franceschini MC; Salvi S; Varesano S; Boccardo S; Vigani A; Morabito A; Canessa PA; Giannoni U; Rosenberg I; Valentino A; Fedeli F; Merlo DF; Ceppi M; Riggio S; Romani M; Saverino D; Poggi A; Pistillo MP
Cancer Immunol Immunother; 2016 Aug; 65(8):909-17. PubMed ID: 27207606
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
Tagliamento M; Di Maio M; Remon J; Bironzo P; Genova C; Facchinetti F; Aldea M; Le Péchoux C; Novello S; Barlesi F; Besse B; Planchard D
J Thorac Oncol; 2024 Jan; 19(1):166-172. PubMed ID: 37567387
[TBL] [Abstract][Full Text] [Related]
17. A deep learning-based model (DeepMPM) to help predict survival in patients with malignant pleural mesothelioma.
Li W; Zhang M; Cai S; Li S; Yang B; Zhou S; Pan Y; Xu S
Transl Cancer Res; 2023 Oct; 12(10):2887-2897. PubMed ID: 37969363
[TBL] [Abstract][Full Text] [Related]
18. Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis.
Chouaid C; Assié JB; Andujar P; Blein C; Tournier C; Vainchtock A; Scherpereel A; Monnet I; Pairon JC
Cancer Med; 2018 Apr; 7(4):1102-1109. PubMed ID: 29479845
[TBL] [Abstract][Full Text] [Related]
19. Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States.
Calthorpe L; Romero-Hernandez F; Miller P; Conroy PC; Hirose K; Kim A; Kirkwood K; Nakakura E; Corvera C; Maker AV; Alseidi A; Adam MA
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612225
[TBL] [Abstract][Full Text] [Related]
20. En bloc resection of the recurrent pleural mesothelioma and reconstruction of the chest wall after immunotherapy: A case report.
Qin C; Xia Q; Chen ZJ; Zhou Q; Zheng X
Thorac Cancer; 2023 Oct; 14(30):3063-3066. PubMed ID: 37658846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
